Oxigene to conduct a $3.1 million at-market issuance sales agreement

McNicoll, Lewis & Vlak helps sell shares to public through offering

By Devika Patel

Knoxville, Tenn., July 8 - Oxigene Inc. will raise $3.1 million through an at market issuance sales agreement, according to a prospectus supplement filed Friday with the Securities and Exchange Commission. The stock sale will be conducted via agent McNicoll, Lewis & Vlak LLC.

Oxigene previously raised $15.18 million under this agreement, as previously reported, and also filed a prospectus supplement that will allow it to sell up to $4 million more of its shares under this agreement.

The offering, which priced July 1, 2010, originally was for up to $4.79 million, but was increased on Jan. 31, June 1 and June 29.

Proceeds will be used for internal research and development programs, preclinical studies and clinical trials with respect to our VDA drug candidates and general corporate purposes.

Oxigene is a pharmaceutical company located in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.